By Julie Steenhuysen
CHICAGO (Reuters) – The U.S.-government-backed Recover study of long COVID will examine Pfizer Inc’s antiviral drug Paxlovid in a clinical trial of 1,700 patients, organizers said on Thursday.
(Reporting By Julie Steenhuysen in Chicago; Editing by Peter Henderson and Mark Porter)
